Get Ahead of It: Testology Inc. Highlights a New Approach to Multi-Cancer Early Detection

BRIGHTON, Mass. - EntSun -- Testology Inc. is highlighting an advanced blood-based cancer screening option designed to identify signals associated with more than 50 types of cancer through a single blood draw, bringing another approach to proactive healthcare to eligible adults.

A Broader Approach to Cancer Screening

Traditional cancer screening typically focuses on individual cancer types. Advances in medical technology are creating new opportunities to look for cancer-associated signals across multiple organs through a single screening test.

The advanced screening offered through Testology Inc. uses specialized DNA methylation analysis to examine cell-free DNA circulating in the bloodstream. This technology is designed to identify patterns associated with more than 50 cancer types, including many for which recommended routine screening tests are not available.

When a cancer-associated signal is detected, the test also predicts the tissue or organ most likely associated with that signal, providing information that can help guide further medical evaluation.

More on EntSun News

• Events by Dubsdread Explores the Art of Authenticity with New Feature on Unique Wedding Experiences
• New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
• Science Conquers Death in Beyond Methuselah, Coming to DVD and Blu-ray December 1
• DecayingMidwest Takes Urban Exploration Worldwide, From Chicago to Japan and Europe
• Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30

One Simple Blood Draw

The collection process involves a routine blood draw performed by a trained technician using specialized collection tubes. No fasting is required.

Following collection, the specimen is sent to a specialized laboratory for analysis. Results are typically available approximately two weeks after the laboratory receives the sample.

For eligible individuals, annual testing may be an option based on healthcare-provider guidance.

Making Proactive Healthcare More Accessible

Testology Inc. continues to expand its laboratory testing services, offering individuals access to specialized blood collection and advanced testing options.

Multi-cancer early detection provides another opportunity for eligible adults, particularly those aged 50 and older or with elevated cancer risk, to discuss additional screening approaches with their healthcare providers.

The goal is simple: encourage informed healthcare decisions and help individuals take a more proactive approach to their health.

More on EntSun News

• Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
• Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
• Coach Bulinda Wright Advances To Top Five In National 'Top Host 2026 Competition'
• Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
• The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th

About Testology Inc.

Testology Inc. is a Boston-based healthcare services provider specializing in laboratory specimen collection, occupational health testing, blood draws, specialized laboratory testing and mobile collection services throughout New England.

Through continued expansion and laboratory partnerships, Testology Inc. aims to increase access to innovative testing options for individuals and organizations.

Ready to get ahead?

Testology Inc.
Phone: 877-211-4447
Website: https://www.testology.org/

Medical information: This blood-based screening test is available by prescription for eligible individuals. It is a screening test, not a diagnostic test. A negative result does not rule out cancer, and a detected signal requires further medical evaluation. Continue all healthcare-provider-recommended routine cancer screenings. HSA/FSA eligibility depends on individual plan requirements.